Evidence map›Paper›PMID 41141963›Full record

ArticleMolecular therapy. Methods & clinical development2025

Generation of high-quality single-stranded DNA for full-length and truncated genome standards of recombinant adeno-associated viruses.

Julia Manz, Raphael Ruppert, Markus Haindl, Jürgen Hubbuch, Tobias Graf, Johannes Pschirer

Abstract read
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Julia ManzGene Therapy Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.
Raphael RuppertGene Therapy Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.
Markus HaindlGene Therapy Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.
Jürgen HubbuchInstitute of Process Engineering in Life Sciences, Section IV: Biomolecular Separation Engineering, Karlsruhe Institute of Technology, 76131 Karlsruhe, Germany.
Tobias GrafPharma Technical Development Analytics, Roche Diagnostics GmbH, 82377 Penzberg, Germany.
Johannes PschirerGene Therapy Technical Development, Roche Diagnostics GmbH, 82377 Penzberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The integrity of the single-stranded DNA (ssDNA) genome of recombinant adeno-associated viral vectors (rAAVs) for gene therapy applications is a critical quality attribute. To monitor this attribute, robust analytical methods, such as long-read sequencing or multiplex PCR, are needed. Due to the heterogeneity of the packaged rAAV payloads, the availability of appropriate ssDNA standards could clearly facilitate the development of these methods and may be used for system suitability testing. However, due to a genome length of up to approximately 4.7 kilobases and the secondary structure of the inverted terminal repeats, such standards are not trivial to produce. Here, we introduce a versatile method that starts with plasmid DNA containing the rAAV genome of interest. After its linearization, the sticky ends are filled in with biotinylated deoxynucleotide triphosphates, and the DNA is bound to streptavidin-coupled beads. With two further restriction enzymes, the plasmid backbone is removed, and finally, the ssDNA is obtained by alkaline strand separation. The quality and purity of the received ssDNA were verified using double-strand synthesis followed by size determination and long-read sequencing. With the presented method, it is possible to generate both full-length and truncated ssDNA standards within one day, contributing to improved quality control of rAAVs.

Indexed as

gene therapygenome integritylong-read sequencingquality controlrAAVssDNA

Identifiers

PMID41141963
PMCPMC12552963

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.